Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcript… Read more
Anbio Biotechnology Class A Ordinary Shares (NNNN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.093x
Based on the latest financial reports, Anbio Biotechnology Class A Ordinary Shares (NNNN) has a cash flow conversion efficiency ratio of 0.093x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.60 Million) by net assets ($17.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Anbio Biotechnology Class A Ordinary Shares - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Anbio Biotechnology Class A Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Anbio Biotechnology Class A Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anbio Biotechnology Class A Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Compania de Transporte de Energia Electrica en Alta Tension Transener SA
BA:TRAN
|
0.118x |
|
Sun Country Airlines Holdings Inc
NASDAQ:SNCY
|
0.126x |
|
Rianlon Corp
SHE:300596
|
0.067x |
|
Partners Value Investments LP
V:PVF-UN
|
0.001x |
|
Magic Software Enterprises Ltd
NASDAQ:MGIC
|
0.064x |
|
Sichuan Swellfun Co Ltd
SHG:600779
|
-0.072x |
|
Jeju Semiconductor Corp
KQ:080220
|
0.022x |
|
Samhaellsbyggnadsbolaget i Norden AB Series D
ST:SBB-D
|
-0.100x |
Annual Cash Flow Conversion Efficiency for Anbio Biotechnology Class A Ordinary Shares (2021–2024)
The table below shows the annual cash flow conversion efficiency of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $17.19 Million | $2.08 Million | 0.121x | +99.61% |
| 2023-12-31 | $14.82 Million | $898.37K | 0.061x | -82.90% |
| 2022-12-31 | $12.55 Million | $4.45 Million | 0.355x | -78.50% |
| 2021-12-31 | $2.54 Million | $4.18 Million | 1.649x | -- |